Progress of treatment-related hemophagocytic syndrome / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 695-697, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-907235
ABSTRACT
Hemophagocytic syndrome (HPS) is a rare, life-threatening inflammatory response syndrome characterized by overactivation of the immune system, which leads to organ damage. Secondary HPS is usually triggered by infection, tumor and autoimmune disease. It has been clinically found that many HPS-like manifestations also occur during drug therapy. This article reviews the related progress of HPS induced by immune checkpoint inhibitors, ibrutinib and lamotrigine, in order to provide a guidance for clinical practice.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Guia de Prática Clínica
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS